Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft Versus Host Disease

New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients

Bone Marrow Transplantation volume 25, pages 965–968 (2000)Cite this article

Abstract

Cyclosporin A (CsA) absorption is variable in bone marrow transplant (BMT) patients compromising the efficacy of graft-versus-host disease prevention. Neoral, a new microemulsion formulation of CsA which has an improved bioavailibility, increases intestinal absorption of the drug with less variable pharmacokinetic parameters in non-BMT patients. In order to predict the best dosage of Neoral when patients are switched from i.v. to oral administration we performed a randomised study comparing two oral doses, either the same or twice the last i.v. dose used after BMT. Fourteen adults were randomised around day 25 after BMT. Whole blood CSA concentrations were measured 2 and 12 h after the oral administration of Neoral on days 0, 7 and 14 to determine residual and maximum concentration, and modified whenever necessary to maintain blood level CsA concentration within therapeutic range (150–250 ng/ml). We found that patients who received twice the last i.v. dose had better concentrations than patients from the other group while toxicity was identical in both groups. We conclude that doubling the last i.v. dose during the switch to oral administration of Neoral gives the best therapeutic range concentration and should be recommended for graft-versus-host prevention. Bone Marrow Transplantation (2000) 25, 965–968.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Holt DW, Mueller EA, Kovarik JM et al. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine Transplant Proc 1994 26: 2935–2939

    CAS  PubMed  Google Scholar 

  2. Holt DW, Johnson A . Cyclosporine microemulsion Biodrugs 1997 7: 175–197

    Article  CAS  Google Scholar 

  3. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course andsuccessful treatment with combination immunosuppression Blood 1981 57: 267–276

    CAS  PubMed  Google Scholar 

  4. Cole E, Keown P, Landsberg D et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients Transplantation 1988 65: 505–510

    Article  Google Scholar 

  5. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation New Engl J Med 1975 292: 832–843, 895–902

    Google Scholar 

  6. Yee GC . Pharmacokinetic and pharmacodynamic studies of cyclosporine in bone marrow transplantation Transplant Proc 1990 22: 1327–1330

    CAS  PubMed  Google Scholar 

  7. Humbert H . Variabilité de la biodisponibilité de la ciclosporine: avantage de la formulation Néoral Thérapie 1996 52: 353–357

    Google Scholar 

  8. Atkinson K . Cyclosporin in bone marrow transplantation Bone Marrow Transplant 1987 1: 265–270

    CAS  PubMed  Google Scholar 

  9. Yee G, McGuire T, Honaker M et al. Serum cyclosporin concentration and risk of acute graft-versus-host disease after allogeneic bone marrow transplantation New Engl J Med 1988 319: 65–70

    Article  CAS  Google Scholar 

  10. Calne RY, White DJG, Thiru S et al. Cyclosporin A in patients receiving renal allografts from cadaver donors Lancet 1978 II: 1323–1327

    Article  Google Scholar 

  11. Gratwohl A, Speck B, Wenk M et al. Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease, and nephrotoxicity Transplantation 1983 36: 40–44

    Article  CAS  Google Scholar 

  12. Feutren G, Wong R, Jin J et al. Safety and tolerability of Neoral in transplant recipients Transplant Proc 1996 4: 2177–2182

    Google Scholar 

  13. Primmett DRN, Levine M, Kovarik JM et al. Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to through levels in predicting drug exposure Therapeutic Drug Monitor 1998 20: 276–283

    Article  CAS  Google Scholar 

  14. Friman S, Bäckman L . A new microemulsion formulation of cyclosporin. Pharmacokinetic and clinical features Clin Pharmacokinet 1996 30: 181–193

    Article  CAS  Google Scholar 

  15. Frei UA, Neumayer HH, Buchholz B et al. Randomised, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients Transplantation 1998 65: 1455–1460

    Article  CAS  Google Scholar 

  16. Storb R, Deeg H, Whitehead J et al. Methotrexate and cyclosporin compared with cyclosporin alone for prophylaxis of acute graft-versus-host disease after bone marrow transplantation for leukemia New Engl J Med 1986 314: 729–735

    Article  CAS  Google Scholar 

  17. Schultz KR, Nevill TJ, Toze CL et al. The pharmacokinetics of oral cyclosporine A (Neoral) during the first month after bone marrow transplantation (BMT) Blood 1997 90: (Suppl.1) 375B

    Google Scholar 

  18. McGuire TR, Honaker M, Lynch JC et al. Renal dysfunction associated with cyclophosphamide (CSA) prophylaxis in HLA matched sibling peripheral blood stem cell transplantation (AlloBSCT): conversion from intravenous CSA to a new oral formulation Blood 1999 94: (Suppl.1) 334a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow Transplant Unit, Hospital Saint Louis, Paris, France

    N Parquet, P Ribaud, G Socié, A Devergie, H Espérou & E Gluckman

  2. Hematology Hospital Paul Brousse, Villejuif, France

    N Parquet

  3. Novartis France, Rueil Malmaison, France

    O Reigneau, H Humbert & M Guignard

Authors
  1. N Parquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O Reigneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Humbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Guignard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Ribaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Socié
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Devergie
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Espérou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Gluckman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parquet, N., Reigneau, O., Humbert, H. et al. New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 25, 965–968 (2000). https://doi.org/10.1038/sj.bmt.1702375

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702375

Keywords

This article is cited by

Search

Advanced search

Quick links